Comparison
CJC-1295 vs Ipamorelin: A Research Comparison
A research-focused comparison of CJC-1295 and ipamorelin — GHRH-receptor agonism versus ghrelin-receptor secretagogue activity for growth hormone release.
Quick Answer
CJC-1295 is a growth hormone–releasing hormone (GHRH) analogue acting at the GHRH receptor, while ipamorelin is a growth hormone secretagogue acting at the ghrelin receptor (GHSR-1a). Both promote growth hormone release in experimental models, but through distinct receptor pathways.
CJC-1295 and ipamorelin are both synthetic peptides investigated for their capacity to stimulate growth hormone release, but they do so through different receptors. CJC-1295 is a growth hormone–releasing hormone (GHRH) analogue acting at the GHRH receptor, while ipamorelin is a growth hormone secretagogue acting at the ghrelin receptor.
This page is a non-promotional scientific reference for researchers. It does not provide performance, anti-ageing, therapeutic, or human-use guidance. Both compounds supplied by Bulk Aussie Peptides are for laboratory research purposes only.
At a Glance
The defining difference is the receptor target. CJC-1295 engages the GHRH receptor, while ipamorelin engages the ghrelin receptor (GHSR-1a). These are two distinct pathways that both converge on the promotion of growth hormone release, which is why the two are often compared.
Compare the Two Compounds
- Receptor target: CJC-1295 acts at the GHRH receptor; ipamorelin acts at the ghrelin receptor (GHSR-1a).
- Compound class: CJC-1295 is a GHRH analogue; ipamorelin is a growth hormone secretagogue.
- Sequence origin: CJC-1295 is derived from native GHRH; ipamorelin is a ghrelin-mimetic.
- Mechanism: both promote growth hormone release in experimental models, but through separate receptor pathways.
- Shared research area: growth hormone secretion and its receptor-mediated stimulation.
Why the Difference Matters in Research
Because the two peptides act through different receptors, they are used together in research to explore whether combined GHRH-receptor and ghrelin-receptor activation produces a different growth hormone response than either pathway alone. This interaction is a central reason the two are studied side by side. Findings remain preclinical.
Analytical Testing
Both compounds are characterised using HPLC for purity and mass spectrometry for identity confirmation. See how to read a peptide Certificate of Analysis.
Individual References
About this page. This article is a non-promotional reference prepared by the Bulk Aussie Peptides research team for educational purposes. It is not medical advice and does not provide dosage, injection, therapeutic, or human-use guidance. Product information is for laboratory research only. How we write and review our research library · Report a correction
Related Articles
Individual Compound Research
CJC-1295 with DAC: A Laboratory Research Reference
A non-promotional scientific reference on CJC-1295 with DAC — GHRH analogue identity, the Drug Affinity Complex modification, molecular characteristics and analytical testing.
Individual Compound Research
CJC-1295 without DAC: A Laboratory Research Reference
A non-promotional scientific reference on CJC-1295 without DAC — unmodified GHRH analogue identity, molecular characteristics, mechanism as studied and analytical testing.
Individual Compound Research
Ipamorelin: A Laboratory Research Reference
A non-promotional scientific reference on ipamorelin — ghrelin receptor secretagogue classification, molecular characteristics, research areas and analytical testing.
Explore the Research Library
Browse our collection of educational reference material.
View All Articles